Compare AQST & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AQST | CTNM |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.4M | 550.7M |
| IPO Year | 2007 | 2024 |
| Metric | AQST | CTNM |
|---|---|---|
| Price | $3.76 | $9.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | $9.33 | ★ $21.43 |
| AVG Volume (30 Days) | ★ 2.4M | 596.9K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $67,430,000.00 | N/A |
| Revenue This Year | $11.13 | N/A |
| Revenue Next Year | $40.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $2.94 | $6.73 |
| 52 Week High | $6.74 | $17.79 |
| Indicator | AQST | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 43.59 | 46.25 |
| Support Level | $3.59 | $8.59 |
| Resistance Level | $4.34 | $13.72 |
| Average True Range (ATR) | 0.25 | 0.77 |
| MACD | 0.02 | 0.23 |
| Stochastic Oscillator | 41.85 | 42.33 |
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.